Global Liquid Biopsy Market Size

1. Global Liquid Biopsy Market Size, Share, Growth Analysis, By Type By End-User- Industry Forecast 2023- 2030 Global Liquid Biopsy Market size was valued at USD 8.7 billion in 2021 and is poised to grow from USD 9.4 billion in 2022 to USD 20.10 billion by 2030, growing at a CAGR of 13.7% during the forecast period (2023- 2030). The global liquid biopsy market has witnessed significant growth due to the increasing prevalence of cancer and the rise in demand for fast and minimally invasive diagnostic tests. Non-small-cell lung cancer is the most common form of lung cancer in the US, with an estimated 235,760 people being diagnosed in 2021. The need for liquid biopsy tests is growing to diagnose and eradicate cancer in a target population. The pandemic has presented various challenges for cancer patients, such as susceptibility to severe infection and interruption of cancer or usual medical care. Despite these challenges, companies have adopted various strategic initiatives to provide safe and easy in-home access for liquid biopsy tests. For example, NeoGenomics, Inc. launched a mobile phlebotomy

2. service for liquid biopsy tests, including NeoLAB and InvisionFirst, in November 2020. The company offers its service through two phlebotomy companies, ExamOne and Metro Health Staffing LLC, for broad geographic coverage to ensure tests are performed efficiently. Liquid biopsy provides an efficient alternative to traditional screening, assisting in early cancer detection and preventing the disease from reaching a stage where it can adversely affect a patient's survival. Liquid biopsies are extremely sensitive and based on blood tests, enabling the evaluation of the severity of the disease and projection of outcomes, revealing the involvement of various organs in the disorder. This is expected to increase R&D funding and further stimulate market growth.

3. Global Liquid Biopsy Market Segmental Analysis The Global Liquid Biopsy market is segmented by type, end-user, and region. Based on type, the market can be segmented into reagents and kits, and instruments. Based on end-user, the market is segmented into hospitals and clinics segment, and research centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. View-More https://www.skyquestt.com/report/liquid- biopsy-market Liquid Biopsy Market Top Player’s Company Profiles •F. Hoffmann-La Roche Ltd (Switzerland) •Thermo Fisher Scientific Inc. (US) •QIAGEN N.V. (Netherlands) •Illumina, Inc. (US) •Guardant Health, Inc. (US) •Biocept, Inc. (US) •Sysmex Corporation (Japan)

4. •Menarini Silicon Biosystems (Italy) •Natera, Inc. (US) •GRAIL, Inc. (US) •Biocartis Group NV (Belgium) •Personal Genome Diagnostics Inc. (US) •Exosome Diagnostics, Inc. (US) •Bio-Rad Laboratories, Inc. (US) •Genomic Health, Inc. (US) •RainDance Technologies, Inc. (US) •OncoCyte Corporation (US) •Adaptive Biotechnologies Corporation (US) •Angle plc (United Kingdom) •Epic Sciences, Inc. (US) About Us: SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

5. Address: 1 Apache Way, Westford, Massachusetts 01886 Phone: USA (+1) 617-230-0741 Email: sales@skyquestt.com LinkedIn Facebook Twitter